spacer
home > pmps > summer 2002 > providing global access to medicines - the role of manufacture and supply
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Providing Global Access to Medicines - The Role of Manufacture and Supply

A universally held objective is patient 'access' to health care interventions in general and medicines in particular - both patent-protected and generic. This represents a particular problem for patients in developing countries, many of whom (for a variety of reasons) do not currently have access. The barriers are multi-factorial: physical and health care infrastructures are often inadequate; financial resources are limited; military, social and political issues abound and country economic policies can have negative effects on health care provision. It is clear that these problems cannot be solved by initiatives in manufacture and supply (M&S), but at the same time some attention has been focused on whether local production, generic competition and technology transfer might make a significant contribution.

Unfortunately, much of the policy discussion within this area has been undertaken without an understanding or appreciation of modern pharmaceutical M&S. This article describes some of the key considerations, and highlights the access-related policy implications. There are five principal considerations, which largely apply equally to branded products and generics:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By David Webber, Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Dr David Webber is a Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) in Geneva. David gained a degree in Biology and a PhD in Animal Physiology from London University, and then undertook postdoctoral research, which led to published papers on stomach function.
He joined Glaxo Pharmaceuticals in 1982, and was responsible for various marketing functions in the UK Operating Company, before assuming a role in the corporate strategy unit. In 1999, David was appointed Public Policy Director in the Corporate Policy and Public Affairs group. In 2000, David was seconded to IFPMA, where he is responsible for policy development in key areas for the industry.

spacer
David Webber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement